Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2015 2
2016 3
2017 2
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
Besarab A, Chernyavskaya E, Motylev I, Shutov E, Kumbar LM, Gurevich K, Chan DT, Leong R, Poole L, Zhong M, Saikali KG, Franco M, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: neff tb. J Am Soc Nephrol. 2016 Apr;27(4):1225-33. doi: 10.1681/ASN.2015030241. Epub 2015 Oct 22. J Am Soc Nephrol. 2016. PMID: 26494833 Free PMC article. Clinical Trial.
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Provenzano R, et al. Among authors: neff tb. Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2. Am J Kidney Dis. 2016. PMID: 26846333 Free article. Clinical Trial.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB. Provenzano R, et al. Among authors: neff tb. Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-91. doi: 10.2215/CJN.06890615. Epub 2016 Apr 19. Clin J Am Soc Nephrol. 2016. PMID: 27094610 Free PMC article. Clinical Trial.
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: neff tb. Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3. Nephrol Dial Transplant. 2015. PMID: 26238121 Free PMC article. Clinical Trial.
Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB. Del Balzo U, et al. Among authors: neff tb. J Pharmacol Exp Ther. 2020 Aug;374(2):342-353. doi: 10.1124/jpet.120.265181. Epub 2020 Jun 2. J Pharmacol Exp Ther. 2020. PMID: 32487538
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH. Chen N, et al. Among authors: neff tb. Nephrol Dial Transplant. 2017 Aug 1;32(8):1373-1386. doi: 10.1093/ndt/gfx011. Nephrol Dial Transplant. 2017. PMID: 28371815 Free PMC article. Clinical Trial.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP. Provenzano R, et al. Among authors: neff tb. J Clin Pharmacol. 2020 Nov;60(11):1432-1440. doi: 10.1002/jcph.1648. Epub 2020 Jun 30. J Clin Pharmacol. 2020. PMID: 32603526 Free PMC article.
11 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page